Welcome to our dedicated page for Q/C Technologies SEC filings (Ticker: QCLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q/C Technologies, Inc. (QCLS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into how Q/C describes its quantum-class, high-performance computing infrastructure business, its licensing agreement with LightSolver for quantum-inspired laser-based processing units, and its focus on applications in the crypto and blockchain domain.
Through Q/C’s Forms 10-K and 10-Q (when filed), investors can review management’s discussion of operations, risk factors, and financial statements related to its quantum-class photonic computing initiatives and related activities. The company’s Current Reports on Form 8-K disclose material events such as private placements of preferred stock and warrants, amendments to transaction documents, consulting agreements, equity incentive plan changes, and stockholder approvals for reverse stock split authorization and share issuance proposals.
Proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals tied to the issuance of common stock underlying preferred stock and warrants, increases in shares available under the 2021 Equity Incentive Plan, and other governance items. Filings such as Form 12b-25 (Notification of Late Filing) explain any reported delays in submitting periodic reports and the company’s stated plans to file within allowed extension periods.
On Stock Titan, these filings are supplemented with AI-powered summaries that aim to clarify key points from lengthy documents, such as the implications of preferred stock terms, voting rights, equity plan amendments, and reverse stock split proposals. Users can also monitor ownership and compensation-related disclosures contained in proxy materials and other filings, as well as any reported unregistered sales of equity securities and warrant issuances. Real-time updates from EDGAR combined with AI explanations help readers navigate Q/C Technologies’ regulatory history and understand the structural aspects of its quantum-class computing business as presented in its official filings.
Gary M. Rauch, listed as Vice President of Finance, reported a change in beneficial ownership of Q/C Technologies, Inc. (QCLS). On 10/03/2025 Mr. Rauch was granted 1,080 restricted stock units that vested immediately and are recorded as common stock with a reported price of $0. Following the reported transaction he beneficially owns 1,080 shares directly. The Form 4 was signed on 10/06/2025. The filing indicates the award was an RSU grant and contains no additional compensation terms, sale, or exercise dates.
Q/C Technologies, Inc. filed an amended report to correct and expand disclosure about equity awards to its leaders. On October 3, 2025, the Board granted an aggregate of 225,000 restricted stock units (RSUs) to its executive chairman, several directors, the chief medical officer, and the vice president of finance under the company’s 2021 Equity Incentive Plan.
The awards include “Initial Grants” of fully vested RSUs issued on the grant date and “Additional Grants” of RSUs that will be issued and fully vest only if stockholders approve an increase in the shares reserved and available under the plan. The amendment is described as limited to adding RSU information for a director that was inadvertently omitted from the original report, with all other information remaining unchanged.
Document type: Shelf registration statement on Form S-3 that includes a prospectus summary, plan of distribution and a list of selling stockholders. The filing lists individual and institutional holders with their current shares and maximum shares to be sold.
The schedule shows Pharmacyte Biotech Inc. holding 9,095,638 shares and a reported post‑sale percentage of 69.21% for one entry, several investors listed with 152,582–312,105 shares and multiple entries showing a 4.99% figure. The document also discloses estimated offering expenses including printing and engraving costs, legal fees of
Q/C Technologies, Inc. entered into an Omnibus Waiver and Amendment with required holders of its Series H preferred stock. The changes include revising “Excluded Securities” so that common stock issued under an approved stock plan can total up to 15.0% of the sum of common shares outstanding on the SPA date and certain preferred stock conversion shares, and adjusting the deadline so the resale registration statement is filed within 30 days after the private placement closing. Holders also waived limits related to issuing consultant warrants, certain registrations, and any missed original registration filing deadline.
The company signed a two-year consulting agreement with James Altucher and Z-List Media, Inc., issuing warrants for up to 400,000 common shares in four tranches at exercise prices of $5.00, $5.00, $7.50, and $10.00 per share. The board also approved 200,000 restricted stock units for directors and senior officers, with a portion vesting immediately and the remaining units vesting if stockholders approve an increase in shares reserved under the 2021 Equity Incentive Plan.